From the 2007 Financial Review......Analysts predict rapid LVAD...

From the 2007 Financial Review......

Analysts predict rapid LVAD market expansion with BTT approval of Thoratec HeartmateII.
HeartmateII will be the first new generation LVAD with US approval.
Will drive “paradigm shift”and “greater adoption”of LVAD therapy.
FDA Panel Meeting 30 November expected to result in PMA approval of HeartmateII for BTT.
Ventracor acknowledged as posing “the most near-term threat to Thoratec”and will benefit from market growth.
Thoratec is the leader (NASDAQ:THOR market cap >US$1Bn). Ventracor will be next to market. Poised to grab significant share.

### Post HMII PMA, VentrAssist will capture most of the BTT trial market!!!